Actinium Pharmaceuticals, Inc. (NYSE:ATNM – Get Free Report) has received a consensus rating of “Moderate Buy” from the five ...

Actinium is a pioneer in the development of targeted radiotherapies intended to meaningfully improve patient outcomes. Actinium is advancing its lead product candidate Actimab-A, a CD33 targeting ...

Actinium-225 PSMA therapy is an emerging treatment for advanced prostate cancer that focuses on delivering targeted radiation ...

Actinium Pharmaceuticals (ATNM) announced that the first clinical trial under its previously announced Cooperative Research and Development ...

Actinium Pharmaceuticals (NYSE:ATNM – Get Free Report)‘s stock had its “buy” rating reaffirmed by investment analysts at HC Wainwright in a research note issued to investors on Tuesday,Benzinga ...

NEW YORK, March 12, 2025 /PRNewswire/ -- Actinium Pharmaceuticals, Inc. (NYSE AMERICAN: ATNM) (Actinium or the Company), a pioneer in the development of targeted radiotherapies, today announced ...

Prostate cancer poses significant challenges for many patients. Radioligand therapies have offered hope by targeting cancer cells with precision. While Lutetium-177 therapy has been effective for many ...

In a report released yesterday, Joseph Pantginis from H.C. Wainwright reiterated a Buy rating on Actinium Pharmaceuticals (ATNM – Research ...

Highlights,Actinium Pharmaceuticals operates in the biotechnology sector, focusing on targeted radiotherapies for oncology treatments.,Institutional participants have adjusted their holdings, ...

NEW YORK - Actinium Pharmaceuticals, Inc. (NYSE AMERICAN: ATNM), whose stock has declined over 83% in the past year according to InvestingPro data, has launched a clinical trial in collaboration ...

NEW YORK - Actinium Pharmaceuticals, Inc. (NYSE AMERICAN: ATNM), whose stock has declined over 83% in the past year according to InvestingPro data, has launched a clinical trial in collaboration with ...